Tandem Diabetes Care, Inc. announced that its t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, now works with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. An early access program for this integration has been initiated in the United States, with scaled availability planned for the second half of 2025. This move expands patient choice and personalization within Tandem's technology ecosystem.
The FreeStyle Libre 3 Plus sensor offers an extended 15-day wear time and transmits automatic glucose readings every minute directly to the pump. This data is also accessible on the Tandem t:slim mobile app, providing users with multiple convenient ways to monitor their glucose trends. This integration allows more CGM users to access the benefits of Control-IQ+ technology, which adjusts insulin every 5 minutes and includes a unique AutoBolus feature.
This development is a first step in Tandem's strategy to connect its portfolio of insulin pumps to Abbott’s FreeStyle Libre 3 Plus sensors worldwide. The company plans to expand access to t:slim X2 users outside of the U.S. beginning later this year. This compatibility is crucial as the American Diabetes Association recommends AID systems as the preferred insulin delivery method for people with type 1 and other types of insulin-deficient diabetes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.